KW-3635のフロセミド利尿に対する作用
スポンサーリンク
概要
- 論文の詳細を見る
The effects of KW-3635 (sodium (<I>E</I>)-11-[2-(5, 6-dimethyl-1-benzimidazolyl) ethylidene]-6, 11-dihydrodibenz-[b, e] oxepine-2-carboxylate monohydrate, CAS 127166-41-0), a novel thromboxane A<SUB>2</SUB> (TxA<SUB>2</SUB>) receptor antagonist, on furosemide diuresis were examined in rats. After an overnight fast, the rats received either saline or drugs, and 6-hr urine samples were collected. Urine volume, urinary excretion of electrolytes and urine TxB<SUB>2</SUB> were measured. The administration of KW-3635 (10, 30 mg/kg, p.o.) or BM-13505 (10, 30 mg/kg) significantly increased the diuretic effect of furosemide (10 mg/kg, p.o.). Neither drug had any effect on urinary excretion of TxB<SUB>2</SUB>. These results demonstrated that the diuretic effect of furosemide was potentiated by TxA<SUB>2</SUB> receptor blockade with KW-3635 or BM-13505. It is suggested that the diuretic effect of furosemide might be modulated by renal production of TxA<SUB>2</SUB> elicited by this drug.
- 社団法人 日本薬理学会の論文
著者
関連論文
- 種々の微生物のリジン要求変異株によるジアミノピメリン酸の生産
- (E)-1-[Bis-(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine dihydrochloride(flunarizine)の脳循環に対する作用について
- Corynebacterium glutamicumおよびArthrobacter paraffineusの変異株によるL-セリンの生産
- KW-3635のフロセミド利尿に対する作用